Irbesartan for the prevention of atrial arrhythmias and cardiac electrical remodeling in patients with hypertension, permanent pacemakers and risk factors for developing atrial fibrillation
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Irbesartan (Primary)
- Indications Supraventricular arrhythmias
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Jul 2007 The expected completion date for this trial is now 1 Jul 2007.
- 20 Sep 2006 New trial record.